Genome-wide association studies indicate that several idiosyncratic adverse drug reactions are highly associated with specific human leukocyte antigen (HLA) alleles. For instance, abacavir, a human immunodeficiency virus reverse transcriptase inhibitor, induces multiorgan toxicity exclusively in patients carrying the HLA-B*57:01 allele. However, the underlying mechanism is unclear due to a lack of appropriate animal models. Previously, we developed HLA-B*57:01 transgenic mice and found that topical application of abacavir to the ears induced proliferation of CD8 þ lymphocytes in local lymph nodes. Here, we attempted to reproduce abacavir-induced liver injury in these mice. However, oral administration of abacavir alone to HLA-B*57:01 transgenic mice did not increase levels of the liver injury marker alanine aminotransferase. Considering the importance of innate immune activation in mouse liver, we treated mice with CpG oligodeoxynucleotide, a toll-like receptor 9 agonist, plus abacavir. This resulted in a marked increase in alanine aminotransferase, pathological changes in liver, increased numbers of activated CD8 þ T cells, and tissue infiltration by immune cells exclusively in HLA-B*57:01 transgenic mice. These results indicate that CpG oligodeoxynucleotide-induced inflammatory reactions and/or innate immune activation are necessary for abacavir-induced HLA-mediated liver injury characterized by infiltration of CD8 þ T cells. Thus, we developed the first mouse model of HLA-mediated abacavir-induced idiosyncratic liver injury. Further investigation will show that the proposed HLA-mediated liver injury model can be applied to other combinations of drugs and HLA types, thereby improving drug development and contributing to the development of personalized medicine.
Idiosyncratic adverse drug reactions (IADRs), which occur rarely but are sometimes severe, usually show delayed onset and are a major obstacle to drug development and clinical use. Although the mechanisms of IADRs is still unclear, it is currently believed that the majority of these reactions are immune-mediated and caused by immunogenic conjugates formed from the reaction of a reactive metabolite of a drug with cellular proteins (Ju and Uetrecht, 2002) . In addition, recent genome-wide association studies have revealed that several, but not all, IADRs are highly associated with specific human leukocyte antigen (HLA) alleles (Usui and Naisbitt, 2017) . For instance, abacavir (ABC)-induced hypersensitivity syndrome (AHS) (Hetherington et al., 2002; Mallal et al., 2002; Martin et al., 2004; Saag et al., 2008) and flucloxacillin- (Daly et al., 2009 ) and pazopanib- induced liver injury are associated with HLA-B*57:01; carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrosis (SJS/TEN) is associated with HLA-B*15:02 (Chung et al., 2004; Hung et al., 2006; Kulkantrakorn et al., 2012; Tangamornsuksan et al., 2013) ; and allopurinol-induced SJS/TEN and drug reactions with eosinophilia and systemic symptoms are associated with HLA-B*58:01 (Cao et al., 2012; Chiu et al., 2012; Ng et al., 2016; Tohkin et al., 2013) . In clinical practice, HLA genotype tests are conducted to prevent onset of HLA-mediated IADRs associated with suspect drugs such as ABC (F.D.A, 2013; Gunthard et al., 2016) or carbamazepine (F.D.A, 2007) .
The HLA system is highly polymorphic and enables host cells to present a variety of peptides derived from exogenous or endogenous antigens and consequently trigger adaptive immune responses via HLA-peptide T-cell receptor interactions. Recent studies demonstrate that unmodified ABC binds directly to the antigen-binding cleft of HLA-B*57:01, thereby altering the peptide repertoire presented by the HLA molecule (Illing et al., 2012; Ostrov et al., 2012) . ABC-bound HLA-B*57:01 presents neopeptides to which T cells are usually tolerant, thereby triggering abnormal T cell responses that lead ultimately to ABC-induced hypersensitivity reactions (Chessman et al., 2008) .
Innate immune reactions play an important role in immunemediated IADRs by enhancing adaptive immune responses (Janeway, 2001) . Innate immune responses are activated in response to pathogens recognized via pathogen-associated molecular patterns or damage-associated molecular patterns. Analysis of a spontaneous adverse drug event reporting database in Japan suggests that infection may make an individual susceptible to SJS/TEN and idiosyncratic drug-induced liver injury (IDILI) (Imatoh et al., 2017) . Similarly, human immunodeficiency virus (HIV) infection or related inflammatory status may also contribute to ABC-induced hypersensitivity reactions since ABC, a HIV reverse transcriptase inhibitor, is administrated to patients with impaired immunity. Toll-like receptor ligands, such as TLR4 and TLR9 ligands, are often used to induce IADRs or autoimmune disease in animal models because they induce inflammation and activate innate immunity (Takai et al., 2015) . For instance, co-administration of CpG oligodeoxynucleotide (CpG-ODN, a TLR9 ligand) and DNA coding for human cytochrome P4502D6/ formiminotransferase cyclodeaminase fusion autoantigen provokes development of autoimmune hepatitis in a HLA-DR humanized mouse model (Yuksel et al., 2015 (Yuksel et al., , 2016 .
Although recent studies show that drug-HLA interactions play an important role in IADRs pathogenesis, the mechanism that governs organ specificity and individual differences in occurrence is unclear. For example, ABC-and flucloxacillininduced IADRs are both associated with HLA-B*57:01, whereas AHS mainly manifests as a multiorgan syndrome with a relatively high odds ratio. In contrast, flucloxacillin mainly causes liver abnormalities, with a much lower odds ratio. In addition, AHS is almost restricted to HLA-B*57:01, whereas about half of HLA-B*57:01-positive individuals tolerate ABC, suggesting that other factors contribute to development of AHS (Illing et al., 2017) . Lack of an appropriate animal model with a humanized immune system carrying specific HLA alleles has prevented meaningful studies of the underlying mechanisms.
Recently, we developed HLA-B*57:01 transgenic (Tg) mice by introducing chimeric HLA-B*57:01 and human b 2 -microglobulin (b 2 m) genes linked to a 2 A peptide into C57BL/6 mice. HLA expression in major organs such as liver, skin, and lymphocyte was confirmed. We then showed that topical application of ABC to the ear-induced proliferation of CD8 þ lymphocytes in local lymph nodes, accompanied by skin abnormalities (Susukida et al., 2017) . ABC-induced liver injury (one manifestation of AHS) is also predominant in HLA-B*57:01-positive patients, but is usually mild and transient (LiverTox, https://livertox.nlm.nih. gov//Abacavir.htm). Further study of ABC-induced liver injury may help to identify crucial parameters, such as the organ specificity of HLA-mediated IADRs. Therefore, the aim of this study was to reproduce HLAmediated ABC-induced liver injury in HLA-B*57:01 Tg mice. To achieve this, we examined the importance of the innate immune system by challenging mice with ABC and CpG-ODN to induce IADRs.
MATERIALS AND METHODS
Materials. Williams' medium E (WME), fetal bovine serum (FBS), and antibiotic-antimycotic (anti-anti) solution were purchased from Life Technologies (Grand Island, New York). ITS þ was purchased from Corning (Bedford, Massachusetts). Collagenase, insulin, dexamethasone, and lactate dehydrogenase (LDH; pig heart) were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). GlutaMAX 100Â and deoxyribonuclease (DNase) were purchased from Sigma-Aldrich (Tokyo, Japan). ABC sulfate was purchased from Carbosynth (Compton, Berkshire, UK). CpG-ODN 1826 was purchased from Fasmac Co., (Kanagawa, Japan).
Animals. HLA-B*57:01 Tg and HLA-B*57:03 Tg (a negative control mouse possessing a closely related allele) mice were originally generated by introducing HLA encoding the corresponding allotype and b 2 m gene, combined with a 2 A peptide sequence, into C57BL/6 mice (Susukida et al., 2017) . All mice used in the study were male, aged 6-10 weeks, and housed in an environment maintained at 25 C with 30%-70% relative humidity and a 12-h light/dark cycle. Animals were treated humanely in accordance with guidelines issued by the National Institutes of Health. All procedures were approved by the Animal Care Committee of Chiba University.
Drug treatment. On days 0, 2, and 4 of the experiment, mice were injected intraperitoneally with 40 lg of CpG-ODN 1826 (TCCATGACGTTCCTGACGTT) dissolved in 200 ll of PBS. CpG-ODN 1826 was phosphorothioate-stabilized to increase stability in vivo. ABC was thoroughly mixed with food and administered to mice at a dose of 1% (w/w).
Measurement of plasma alanine aminotransferase. Alanine aminotransferase (ALT), a biomarker of liver injury, was measured by collecting blood from the saphenous vein on days 0, 3, 7, 10, and 14. Briefly, blood samples were centrifuged for 3 min at 2000 Â g to obtain plasma. Then, 50 ll of ALT substrate (200 mM DLalanine, 1.8 mM a-ketoglutaric acid, and 0.5% chloroform in PBS (pH 7.4)) was preincubated at 37 C, followed by addition of 10 ll of plasma at 37 C for 30 min. Next, 50 ll of 0.35 mg/ml 2, 4-dinitrophenyl hydrazine in 1 N HCl was added and incubated at room temperature for 20 min. Finally, 500 ll of 0.4 N NaOH was added at room temperature for 5 min and absorbance at 492 nm was measured in a Multiskan JX (Labsystems, Inc., Vienna, Virginia). A calibration curve was constructed using 1.5 mM sodium pyruvate and 0.5% chloroform in PBS (pH 7.4).
Measurement of ABC concentration in plasma. The concentration of ABC in plasma was measured by collecting blood from the inferior vena cava, followed by LC-MS/MS (Bruker Daltonics Inc., Billerica, Massachusetts). Briefly, plasma samples were passed through an Oasis HLB Extraction Cartridge column (Waters, Milford, Massachusetts), evaporated to dryness, redissolved in 100 ll of the mobile phase, and analyzed in a mass spectrometer by electrospray ionization in positive ion mode. The m/z of ABC was 287.0!190.8. The HPLC column was a Wakosil-II 3C18 HG (2.0 Â 150 mm) analytical column (Wakopak, Osaka, Japan), the mobile phase flow rate was 0.2 ml/min, and the mobile phase was 0.1% formic acid in water/acetonitrile (50/50).
Hepatocyte isolation and purification. Mouse hepatocytes were isolated using a 2-step perfusion method, as reported previously in Liu et al. (2016) , with some modifications. Briefly, mice were anesthetized and the livers were perfused first with Ca 2þ /Mg 2þ -free perfusion buffer, followed by collagenase (0.33 g/l) buffer (perfusion buffer without EGTA). Isolated hepatocytes were purified on 50% isotonic Percoll (GE Healthcare, Tokyo, Japan).
Hepatocyte viability was determined in a trypan blue exclusion assay. Live hepatocytes were counted and seeded onto collagen-coated 96-well plates at a density of 4.125 Â 10 4 cells/ well in 100 ll of plating medium (WME medium containing 5% FBS, 5 lg/ml insulin, 1 lM dexamethasone, anti-anti, GlutaMAX, 15 mM HEPES) and cultured at 37 C in a humidified atmosphere of 95% air/5% CO 2 . After 2 h, unattached cells were removed by exchanging the medium for culture medium (WME medium containing 1% ITS þ , 0.1 lM dexamethasone, anti-anti, and GlutaMAX).
Measurement of LDH.
After culture for 24 h, hepatocytes were exposed to ABC for 24 h and cytotoxicity was assessed by measuring LDH release using the TaKaRa LDH cytotoxicity detection kit (TaKaRa Bio Inc., Shiga, Japan), according to the manufacturer's instructions. Absorbance was measured using a Lab Systems Multiskan JX multiwell plate reader at the wavelength of 492 nm. LDH release was calculated as follows: (% control) ¼ (experiment-"low control")/("high control"-"low control") Â 100%. "Low control" represents LDH released from cells treated with Milli Q water, and "high control" represents LDH released from cells treated with 0.25% Triton X-100.
Histology and immunohistochemistry. After sacrifice, mouse livers were removed, embedded in O.C.T. compound (Sakura Finetek, Tokyo, Japan), and immediately frozen in liquid nitrogen. Frozen sections (8 lm) were cut, mounted in slides, air-dried, fixed in 4% paraformaldehyde in phosphate buffer (Nacalai Tesque, INC. Kyoto, Japan) for 10 min, washed with PBS, and stained with hematoxylin and eosin (H&E). For immunohistochemistry, sections were mounted, air-dried, fixed with acetone for 10 min, and washed twice with PBS. Slides were then blocked with 10% FBS for 1 h at room temperature. Each slide was incubated overnight at 4 C with an appropriate primary antibody. The following primary antibodies were used: mouse antiCD4 (clone: EPR19514, Abcam, Cambridge, Massachusetts) and mouse anti-CD8 (clone: YTS169.4, Abcam), both diluted 1:100 in PBS containing 0.3% Triton-100 and 0.1% bovine serum albumin. The slides were washed twice with PBS and then incubated for 1 h at room temperature with the corresponding Alexa-labeled secondary antibody (Thermo Fisher, Eugene, Oregon) and Hoechst 33342 (Thermo Fisher) in PBS containing 0.1% bovine serum albumin. Stained slides were washed twice with PBS and sealed with Vectashield (Vector Laboratories, Inc. Burlingame, California). The H&E and immunostained slides were observed under a fluorescence microscope (KEYENCE-BZ-Z710, Keyence, Osaka, Japan).
Isolation of liver mononuclear cells. Mouse liver mononuclear cells (LMNCs) were isolated as reported previously (Hintermann et al., 2012) , with some modifications. Briefly, mouse liver was perfused with ice cold PBS, placed in 20 ml of collagenase buffer (0.1 mg/ml collagenase, 0.01 mg/ml DNase, and 2.5% FBS in PBS) in a petri dish on ice, and cut into small pieces using scissors. Liver chunks were transferred to a 100 lm pore size cell strainer (Becton Dickinson Labware, Franklin Lakes, New Jersey) and pushed through using a glass syringe plunger. The cell suspension was collected and filtered twice through the strainer. The liver cell suspension was incubated at 37 C for 60 min, with gentle mixing every 15 min. The suspension was then centrifuged at 30 Â g for 3 min at 4 C, and the supernatant was transferred to a fresh tube. The tube was centrifuged at 640 Â g for 10 min at 4 C. The cells were then incubated in red cell lysis buffer (containing 0.15 M NH 4 Cl, 10 mM KHCO 3 , 0.1 mM Na 2 EDTA, pH 7.4) for 2 min at room temperature and washed with PBS containing 2% FBS. The cells were centrifuged again, and the pellets were resuspended in 20 ml of 40% Percoll buffer (GE Healthcare) in PBS, followed by centrifugation at 600 Â g for 20 min at 4 C. The supernatant was discarded, and the pellets were washed with 2% FBS in PBS. Finally, the pellets were resuspended and used as LMNCs.
Flow cytometry analysis. LMNCs were counted using a hemocytometer and then stained on ice for 30 min with antiCD3 (FITC), antiCD4 (PE), antiCD8 (PECY7), antiCD69 (FITC), antiCD44 (FITC), antiCD62L (FITC), and antiCD279 (PE) antibodies, all purchased from TONBO Biosciences (San Diego, California). The cells were then washed in 2 ml of 2% FBS in PBS and centrifuged at 700 Â g for 6 min. The cells were then washed twice, resuspended in 500 ll of 2% FBS in PBS, kept on ice, and protected from light prior to flow cytometric detection using an EC800 flow cytometer (Sony, Tokyo, Japan). Data were analyzed using Flow Logic software (Bay Bioscience Co., Ltd., Tokyo, Japan).
Statistical analysis. Data are presented as the mean 6 SD. Statistical comparisons were performed using Student's t-test for 2 groups or ANOVA followed by Tukey's test or Fisher's least significant difference (LSD) test for multiple groups (GraphPad Software, San Diego, California). p values < .05 were considered significant.
RESULTS

ABC and CpG-ODN Induce Liver Injury in HLA-B*57:01 Tg Mice
To reproduce HLA-mediated ABC-induced liver injury in mice, we first treated HLA-B*57:01 Tg mice, their littermates, and HLA-B*57:03 Tg mice with ABC for up to 4 weeks. However, we did not observe increased levels of ALT in plasma samples from any of these groups (data not shown), suggesting that HLA phenotype alone does not trigger ABC-induced liver injury. Considering the importance of innate immune responses to the development of IDILI, we treated HLA-B*57:01 Tg mice and HLA-B*57:03 Tg mice with ABC for 2 weeks. At the same time, mice received intraperitoneal injections of CpG-ODN on days 0, 2, and 4; we then examined time-dependent changes in plasma ALT levels. As shown in Figure 1A , ALT levels on day 3 were within the normal range, but increased thereafter and peaked on day 7. Levels in HLA-B*57:01 Tg mice treated with ABC and CpG-ODN returned to normal on day 14. In contrast, ALT levels in HLA-B*57:03 mice treated with ABC and CpG-ODN did not change throughout the treatment period. Furthermore we next measured more precise time-dependent changes in plasma ALT levels in HLA-B*57:01 Tg mice treated with ABC and CpG-ODN as described above. Plasma ALT levels were measured on day 5, 6, 7, 8, and 9 (Supplementary Figure 1) . ALT levels were unchanged on day 5, thereafter peaked on day 7 or day 8. We chose to use day 7 data to evaluate ABC-induced liver injury in the following experiments. Next, we evaluated ALT levels in HLA-B*57:01 Tg mice, their littermates, and HLA-B*57:03 Tg mice on day 7 after treatment with ABC alone, CpG-ODN alone, or a combination of both. As shown in Figure 1B , ALT levels were significantly higher only in HLA-B*57:01 Tg mice treated with ABC and CpG-ODN. To confirm that CpG-ODN alone plus HLA did not affect the plasma concentration of ABC after oral administration, we fed HLA-B*57:01 Tg mice, their littermates, and HLA-B*57:03 Tg mice with ABC alone for 7 days, or coadministered 3 injections of CpG-ODN (on days 0, 2, and 4). We then measured plasma concentrations of ABC (Supplementary Figure 2) . There was no significant difference in plasma ABC levels between the groups; the total mean ABC plasma concentration was 34.5 lM, which is about 3-fold higher than the human C max (12.6 lM) (Wang et al., 1999) . Next, we weighed the liver and spleen to examine whether liver injury induced by ABC caused organ enlargement. After treatment with ABC and CpG-ODN, the livers of HLA-B*57:01 Tg mice were heavier than those of HLA-B*57:03 Tg mice and HLA-B*57:01 Tg littermates, but the difference was not statistically significant (p ¼ .4892) ( Figure 1C ). In contrast, the spleens of HLA-B*57:01 Tg mice weighed significantly more than those of other groups ( Figure 1D ). Next, we examined the total liver mononuclear cell (LMNC) population. LMNCs were isolated from HLA-B*57:01 Tg mice, their littermates, and HLA-B*57:03 Tg mice treated with ABC for 7 days, and injected with CpG-ODN on days 0, 2, and 4. The absolute number of LMNCs per gram of liver was significantly higher in HLA-B*57:01 Tg mice treated with ABC and CpG-ODN than in littermate mice or HLA-B*57:03 Tg mice treated with ABC and CpG-ODN ( Figure 1E ). Collectively, these data suggest that ABC alone does not induce ALT elevation in mice, whereas ABC plus CpG-ODN increases ALT levels in HLA-B*57:01 Tg mice. In addition, the enlarged spleen and increased LMNCs in HLA-B*57:01 Tg mice suggests that an immune response plays a role in ABC-induced liver injury.
ABC-Induced Liver Injury Is Associated With Intrahepatic Mononuclear Cell Infiltration
To further characterize the liver injury in HLA-B*57:01 Tg mice, we performed histological examination of liver tissue from HLA-B*57:03 and HLA-B*57:01 Tg mice treated with ABC for 7 days and receiving CpG-ODN injections on days 0, 2, and 4. As shown in Figure 2A , white spots (arrows), which are a hallmark of hepatic lesions, were observed only in the liver lobes of HLA-B*57:01 Tg mice treated with ABC and CpG-ODN.
No pathological effects were observed in liver from control HLA-B*57:03 Tg mice treated with ABC and CpG-ODN. Examination of H&E-stained liver sections revealed mononuclear cell infiltration and necro-inflammatory foci in the liver of HLA-B*57:01 Tg mice treated with ABC and CpG-ODN; these phenomena were absent from the livers of control HLA-B*57:03 Tg mice ( Figure 2B ). To further characterize the infiltrating intrahepatic mononuclear cells, we stained tissue for CD4 þ and CD8 þ T cells.
No significant infiltration of the liver by CD4 þ T cells was observed in HLA-B*57:03 or HLA-B*57:01 mice treated with ABC and CpG-ODN ( Figure 3A ). In contrast, liver from HLA-B*57:01 mice (but not HLA-B*57:03 Tg mice) treated with ABC and CpG-ODN showed significant infiltration by CD8 þ T cells ( Figure 3B ).
We also evaluated other symptoms of AHS in HLA-B*57:01 Tg mice treated with ABC and CpG-ODN. Histological examination of skin, stomach, jejunum, heart, lung, and kidney, along with assessment of mesenteric lymph node enlargement and hematology was conducted on day 7. Skin from HLA-B*57:01 Tg mice treated with ABC and CpG-ODN showed evidence of immune cell infiltration (arrows); this was not the case for HLA-B*57:03 Tg mice (Supplementary Figure 3) . We observed enlarged mesenteric lymph nodes (Supplementary Figure 4) only in HLA-B*57:01 Tg mice treated with ABC and CpG-ODN. Also, we observed increased atypical lymphocytes and decreased white blood cells in one of the 2 HLA-B*57:01 Tg mice treated with ABC and CpG-ODN, but not in untreated groups or HLA-B57:03 group (data not shown). These symptoms are at least partially consistent with the clinical presentation of AHS.
Flow Cytometry Analysis of Hepatic Immune Cell Composition
We next examined the composition of LMNCs in the liver. LMNCs were isolated from HLA-B*57:01 Tg mice, their littermates, and HLA-B*57:03 Tg mice treated with ABC for 7 days and injected with CpG-ODN on days 0, 2, and 4. We stained (03) were treated with ABC (1% (w/w) in food) for 7 days, an intraperitoneal injection of CpG-ODN (40 lg/mouse) on days 0, 2, and 4, or a combination of both. Plasma ALT levels were determined after 7 days (n ¼ 6-16/group). C-E, Liver weight/body weight ratio, spleen weight/body weight ratio, and number of LMNCs in mice after 7 days of treatment (n ¼ 6/group). Isolated LMNCs were counted using a hemocytometer and normalized by corresponding liver weight. Data are expressed as the mean 6 SD.
ns, not significant; *p < .05; **p < .01; ***p < .001 (Student's t-test or ANOVA, followed by Tukey's test or the LSD test). Untreated mice were used as controls. LMNCs were isolated from liver, and the proportion of CD3
cells (B), and CD3
þ CD8 þ T cells (C) in the LMNC population was determined by flow cytometry. Data are expressed as the mean 6 SD (n ¼ 3/group). ns, not significant; *p < .05; **p < .01; ***p < .001 (ANOVA, followed by Tukey's test).
that CD3
tant role in ABC-induced liver injury.
Infiltrating CD8 1 T Cells Are Activated and Show Upregulated
Expression of PD-1 To further investigate the CD8 þ T cells infiltrating the liver of mice treated with ABC and CpG-ODN, we treated HLA-B*57:03 Tg mice and HLA-B*57:01 Tg mice with ABC for 7 days and administered CpG-ODN on days 0, 2, and 4. On day 7, mice were sacrificed and LMNCs were isolated and stained with antibodies specific for CD69 (an early activation marker), CD44 (a pan-Tcell activation marker), CD62L (a naïve T-cell marker), CD279 (PD-1; a marker of immune suppression and a marker of activated T cells since its expression is induced only after T-cell activation) (Ostrand-Rosenberg et al., 2014) , and CD8. Cells were then examined by flow cytometry. As shown in Figures 5A-C , the percentages of
cells in the LMNC population from ABC-and
CpG-ODN-treated HLA-B*57:01 Tg mice were significantly higher than those in HLA-B*57:03 Tg mice, implying that most infiltrating CD8 þ T cells were activated. Of note, CD279 (PD-1) was higher in HLA-B*57:01 Tg mice treated with ABC plus CpG-ODN than in HLA-B*57:03 Tg mice treated with ABC plus CpG-ODN ( Figure 5D ), suggesting that recovery of ALT on day 14 after ABC and CpG-ODN treatment ( Figure 1A ) may be explained by acquisition of immune tolerance after treatment.
DISCUSSION
AHS is a systemic drug-induced hypersensitive reaction involving multiple organs (Hughes et al., 2008) . As a symptom of AHS, ABC-induced liver injury is mild, anicteric, and typically associated with the HLA-B*57:01 haplotype (LiverTox, https://livertox. nlm.nih.gov//Abacavir.htm.). Studies of ABC-induced liver injury have shed light on HLA-mediated IADRs. In preliminary experiments, ABC (up to 10 mM) did not induce toxicity in primary hepatocytes isolated from HLA-B*57:01 Tg mice (data not shown). These data suggest that direct toxicity to hepatocytes 
T cells within the LMNC population was detected by flow cytometry. Data are expressed as the mean 6 SD (n ¼ 3/group). ns, not significant; *p < .05; ***p < .001 (Student's t-test).
does not contribute to ABC-induced liver injury. Next we treated HLA-B*57:01 Tg mice and their littermates with ABC alone for up to 4 weeks. However, plasma ALT levels were not elevated in any of the groups (data not shown), which suggest that mimicking of genetic susceptibility, expressed as DILI-associated HLA alleles in mice, is not sufficient for reproducing the complex pathogenesis leading to DILI in human. ABC is used to treat HIV infection. Most patients with HIV also have other infections; thus virus infection and the resulting inflammatory environment may render individuals more susceptible to ABC-induced liver injury. To increase the innate immune response and mimic the inflammatory environment, mice received immunostimulatory CpG-ODN; we then examined their susceptibility to ABC-induced liver injury. Figures 1A  and 1B show that neither ABC nor CpG-ODN alone increased ALT in HLA Tg mice or their littermates, whereas ABC combined with CpG-ODN resulted in mild ALT elevation in HLA-B*57:01 Tg mice. Of note, ALT levels in HLA-B*57:01 Tg mice peaked on day 7 and recovered by day 14, which is consistent with the clinical manifestations of ABC-induced liver injury, ie, delayed onset and transient (LiverTox, https://livertox.nlm.nih.gov//Abacavir. htm.). In addition, hepatic infiltration and activation of CD8 þ T was observed in HLA-B*57:01 Tg mice treated with ABC and CpG-ODN, which was supported by the plasma ALT profile (Figs. 3B and 4C) . These data indicate that ABC-induced HLAmediated liver injury is caused mainly by CD8 þ T cells, and that
CpG-ODN-induced inflammatory reactions or innate immune activation is necessary for ALT elevation. The role of CD8 þ T cells in the development of immune-mediated liver injury is accepted in some experimental models of drug-induced liver injury, including models of injury induced by flucloxacillin (Nattrass et al., 2015) , amodiaquine (Mak and Uetrecht, 2015) , halothane (You et al., 2010) , and D-penicillamine (Metushi et al., 2014) . Moreover, a previous study reported a significant positive correlation between CD8 þ T cell numbers and ALT elevation in HIV patients, although the causative drug was not necessarily restricted to ABC (Mulu et al., 2013) . Since ABC-induced liver injury is rarely reported, the role of CD8 þ T cells in a clinical situation requires further study. AHS is mediated by adaptive immune responses, which are complicated process in vivo. Traditionally, T-cell activation is mediated by antigen-presenting cells (APCs). McCluskey et al. reported that, in vitro, APCs are required to mediate intracellular processing or modification of the drug to create a ligand during ABC-specific T cell responses (Chessman et al., 2008) . In contrast, Pichler et al. proposed that T-cell activation, coupled with ABC exposure, is independent of APCs because naïve and memory T cells are activated by ABC alone in vitro (Adam et al., 2014) . At present, the precise mechanism(s) underlying ABC-induced T cell responses in vivo are unclear. Further studies using our model mice may help us to identify these mechanism(s).
The liver is a tolerogenic organ since it is exposed to antigens derived from the gut and to modified proteins derived from reactive metabolites in food (Uetrecht and Kaplowitz, 2015) . In addition, expression of immunosuppressive signaling proteins such as programmed cell death ligand 1 in murine liver nonparenchymal cells and T cells is higher than that in human equivalents (Keir et al., 2008) . Therefore, overcoming immune tolerance may be a key factor for development of mouse models of IDILI. Indeed, breakdown of immune tolerance due to deficiency of CD4 þ cells or PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), provokes flucloxacillin-and amodiaquineinduced idiosyncratic liver injury in mice (Metushi et al., 2015b; Nattrass et al., 2015 (Buatois et al., 2017; Klinman, 2004; Sacher et al., 2002) . In addition, CpG-ODN upregulates expression of adhesion and costimulatory molecules on APCs and hepatocytes, which may support activation of adaptive immunity (Hartmann et al., 2000; Jakob et al., 1998; Sacher et al., 2002) . In fact, we measured expression of TNF-a, IFN-c, and IL-12 mRNA, and CXCL9 and CXCL10 mRNA in mouse liver 6 h after injection of CpG-ODN. Expression of these cytokines and chemokines in liver was upregulated (data not shown), supporting the hypothesis that CpG-ODN activates the innate immune system and induces T cell homing, which ultimately leads to ABC-induced liver injury. Contribution of innate stimulation by TLRs and/or disease status on the onset of IDILI is complicated. Uetrecht et al tried to develop animal models of IDILI by stimulating the immune system with agents such as lipopolysaccharide (TLR4 ligand) and poly-IC (TLR3 ligand), but these attempts were unsuccessful (Metushi et al., 2015b) . In addition, preexisting liver disease or inflammatory conditions such as inflammatory bowel disease do not appear to be a major risk factor for IDILI (Uetrecht and Kaplowitz, 2015) . On the other hand, coadministration of CpG-ODN and DNA encoding human cytochrome P4502D6/formiminotransferase cyclodeaminase fusion autoantigen induces autoimmune hepatitis in a HLA-DR humanized mouse model (Yuksel et al., 2015) . In 2017, a study analyzing a spontaneous adverse drug event reporting database in Japan suggested that infection may make an individual susceptible to SJS/TEN and IDILI (Imatoh et al., 2017) . ABC is used to treat HIV infection; however, most patients with HIV also have other infections or diseases that may provide a second danger signal that activates the innate immune response. Here, we chose to use CpG-ODN to stimulate immune responses and concluded that coadministration of ABC plus CpG-ODN to HLA Tg mice effectively reproduces the ABC-induced liver injury observed in patients. Further investigations will be needed to confirm that the HLAmediated liver injury model proposed herein can be applied to other combinations of drugs and HLA types.
Immune tolerance plays an important role not only in onset of, but also recovery from drug-induced liver injury and autoimmune hepatitis (Chakraborty et al., 2015; Metushi et al., 2015a) . In clinical practice, those with ABC-induced liver injury recover rapidly, indicating involvement of immune tolerance. Here, we also found that elevated ALT in HLA-B*57:01 Tg mice treated with ABC and CpG-ODN returned to normal by day 14. Therefore, we measured expression of PD-1 (CD279), which plays an important role in suppression of immune responses and promotion of self-tolerance (Keir et al., 2008) . The numbers of CD8 þ
CD279
þ T cells in HLA-B*57:01 Tg mice treated with ABC and CpG-ODN on day 7 were higher than those in HLA-B*57:03 Tg mice treated with ABC and CpG-ODN, indicating that immune tolerance dampens progression of ABC-induced liver injury in this experimental model. As a preliminary experiment, we have investigated ABC-specific T-cell response ex vivo. However, we could not observe T cell response in LMNCs from HLA-B*57:01 Tg mice treated with ABC and CpG-ODN (data not shown), which also may be associated with immune tolerance. Genetic polymorphism of genes involved in immune tolerance, such as PD-1 and CTLA-4, is associated with susceptibility to autoimmune disease and with anti-tumor immunity. For example, PD-1 gene polymorphisms rs2227981 and rs2227982, and CTLA-4 gene polymorphism s231775, are a high-risk factor for autoimmune disease but a low-risk factor for cancer; this is because they do not suppress immune responses as much as other haplotypes (Chua et al., 2015; Haghshenas et al., 2017; Jaiswal et al., 2014; Patel et al., 2016; Ting et al., 2016; Zhang et al., 2016) . However, no report has examined susceptibility to IADRs. Considering that HLA-mediated IDILI are associated with the immune system, it is possible that polymorphism of immune tolerance genes may affect susceptibility to immune-mediated liver injury, thereby accounting for the large interindividual differences in onset and/or aggravation of liver injury. In summary, we developed a mouse model of HLA-mediated liver injury by treating HLA-B*57:01 Tg mice with ABC and CpG-ODN. Further studies of this model may increase our understanding of the detailed mechanism(s) underlying HLAmediated IADRs and facilitate prediction of IADRs during drug development; this should contribute to the development and clinical application of personalized medicine.
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